Amgen Argues For Denial Of Sandoz’s High Court Review Of Patent Case

(April 14, 2016, 2:04 PM EDT) -- WASHINGTON, D.C. — Amgen Inc. and Amgen Manufacturing Limited (Amgen, collectively) on March 21 asked the U.S. Supreme Court to deny a request by Sandoz Inc. to review whether an appellate court erred in finding that biosimilar makers must wait until their products receive U.S. Food and Drug Administration approval before providing 180-day advance notice of sales (Sandoz, Inc. v. Amgen, Inc. and Amgen Manufacturing, Ltd., No. 15-1039, U.S. Sup.).

(Respondents’ opposition brief available. Document #78-160418-003B.)

The Federal Circuit U.S. Court of Appeals on Oct. 16,...
To view the full article, register now.